ArticleInternational journal of hematology2016

Changes from imatinib mesylate to second generation tyrosine kinase inhibitors improve renal impairment with imatinib mesylate in chronic myelogenous leukemia.

Akihisa Hino et al.PubMed ↗Publisher ↗

No numbers read from the abstract.